Literature DB >> 28559253

Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase.

Maryam Ehteshami1, Longhu Zhou1, Sheida Amiralaei1, Jadd R Shelton1, Jong Hyun Cho1, Hongwang Zhang1, Hao Li1, Xiao Lu1, Tugba Ozturk1, Richard Stanton1, Franck Amblard1, Tamara R McBrayer2, Steven J Coats2, Raymond F Schinazi3.   

Abstract

Nucleoside analog inhibitors (NAIs) are an important class of antiviral agents. Although highly effective, some NAIs with activity against hepatitis C virus (HCV) can cause toxicity, presumably due to off-target inhibition of host mitochondrial RNA polymerase (POLRMT). The in vitro nucleotide substrate specificity of POLRMT was studied in order to explore structure-activity relationships that can facilitate the identification of nontoxic NAIs. These findings have important implications for the development of all anti-RNA virus NAIs.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  antiviral agents; hepatitis C virus; toxicity

Mesh：

Substances：

Year:  2017        PMID： 28559253      PMCID： PMC5527647          DOI： 10.1128/AAC.00492-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture.

Authors:  Lieven J Stuyver; Tony Whitaker; Tamara R McBrayer; Brenda I Hernandez-Santiago; Stefania Lostia; Phillip M Tharnish; Mangala Ramesh; Chung K Chu; Robert Jordan; Junxing Shi; Suguna Rachakonda; Kyoichi A Watanabe; Michael J Otto; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 2.  A brief overview of mechanisms of mitochondrial toxicity from NRTIs.

Authors:  James J Kohler; William Lewis
Journal:  Environ Mol Mutagen       Date:  2007 Apr-May       Impact factor: 3.216

3.  Calamitous HCV trial casts shadow over nucleoside drugs.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2012-11       Impact factor: 54.908

4.  Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.

Authors:  Tariq Ahmad; Philip Yin; Jeffrey Saffitz; Paul J Pockros; Jacob Lalezari; Mitchell Shiffman; Bradley Freilich; Joann Zamparo; Kyle Brown; Dessislava Dimitrova; Monica Kumar; Doug Manion; Margo Heath-Chiozzi; Robert Wolf; Eric Hughes; Andrew J Muir; Adrian F Hernandez
Journal:  Hepatology       Date:  2015-05-26       Impact factor: 17.425

5.  Human mitochondrial RNA polymerase: evaluation of the single-nucleotide-addition cycle on synthetic RNA/DNA scaffolds.

Authors:  Eric D Smidansky; Jamie J Arnold; Shelley L Reynolds; Craig E Cameron
Journal:  Biochemistry       Date:  2011-05-12       Impact factor: 3.162

Review 6.  Strategies to reduce late-stage drug attrition due to mitochondrial toxicity.

Authors:  James A Dykens; Lisa D Marroquin; Yvonne Will
Journal:  Expert Rev Mol Diagn       Date:  2007-03       Impact factor: 5.225

Review 7.  Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance.

Authors:  Luis Menéndez-Arias; Mar Álvarez; Beatriz Pacheco
Journal:  Curr Opin Virol       Date:  2014-05-09       Impact factor: 7.090

8.  Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094.

Authors:  Maryam Ehteshami; Sijia Tao; Tugba Ozturk; Longhu Zhou; Jong Hyun Cho; Hongwang Zhang; Sheida Amiralaei; Jadd R Shelton; Xiao Lu; Ahmed Khalil; Robert A Domaoal; Richard A Stanton; Justin E Suesserman; Biing Lin; Sam S Lee; Franck Amblard; Tony Whitaker; Steven J Coats; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

9.  Antiviral Nucleotide Incorporation by Recombinant Human Mitochondrial RNA Polymerase Is Predictive of Increased In Vivo Mitochondrial Toxicity Risk.

Authors:  Martijn Fenaux; Xiaodong Lin; Fumiaki Yokokawa; Zachary Sweeney; Oliver Saunders; Lili Xie; Siew Pheng Lim; Marianne Uteng; Kyoko Uehara; Robert Warne; Wang Gang; Christopher Jones; Satya Yendluri; Helen Gu; Keith Mansfield; Julie Boisclair; Tycho Heimbach; Alexandre Catoire; Kathryn Bracken; Margaret Weaver; Heinz Moser; Weidong Zhong
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

10.  Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Anne B Eldrup; Charles R Allerson; C Frank Bennett; Sanjib Bera; Balkrishen Bhat; Neelima Bhat; Michele R Bosserman; Jennifer Brooks; Christine Burlein; Steven S Carroll; P Dan Cook; Krista L Getty; Malcolm MacCoss; Daniel R McMasters; David B Olsen; Thazha P Prakash; Marija Prhavc; Quanlai Song; Joanne E Tomassini; Jie Xia
Journal:  J Med Chem       Date:  2004-04-22       Impact factor: 7.446
View more
  3 in total

1.  Simple In Vitro Assay To Evaluate the Incorporation Efficiency of Ribonucleotide Analog 5'-Triphosphates into RNA by Human Mitochondrial DNA-Dependent RNA Polymerase.

Authors:  Gaofei Lu; Gregory R Bluemling; Shuli Mao; Michael Hager; Bharat P Gurale; Paul Collop; Damien Kuiper; Kasinath Sana; George R Painter; Abel De La Rosa; Alexander A Kolykhalov
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  Identification of Structural and Molecular Features Involved in the Transport of 3'-Deoxy-Nucleoside Analogs by Human Equilibrative Nucleoside Transporter 3.

Authors:  Md Fazlur Rahman; Radhika Raj; Rajgopal Govindarajan
Journal:  Drug Metab Dispos       Date:  2018-03-12       Impact factor: 3.922

Review 3.  Targeting Mitochondrial Metabolism and RNA Polymerase POLRMT to Overcome Multidrug Resistance in Cancer.

Authors:  Hui-Jing Yu; Guan-Li Xiao; Yu-Ying Zhao; Xin-Xin Wang; Rongfeng Lan
Journal:  Front Chem       Date:  2021-12-16       Impact factor: 5.221
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.